Sgmoscati Hospital Of Avellino

Avellino, Italy

Sgmoscati Hospital Of Avellino

Avellino, Italy
SEARCH FILTERS
Time filter
Source Type

Sacco P.C.,Sgmoscati Hospital Of Avellino | Maione P.,Sgmoscati Hospital Of Avellino | Rossi A.,Sgmoscati Hospital Of Avellino | Barecshino M.A.,Sgmoscati Hospital Of Avellino | And 7 more authors.
Frontiers in Bioscience - Landmark | Year: 2014

In terms of both incidence and mortality, lung tumor is the most common cancer in the world today. Among lung tumors, 80% are classified as non-small-cell lung cancer (NSCLC) and are mostly diagnosed at an advanced stage (either locally advanced or metastatic disease). Platinum-based doublet chemotherapy, the standard treatment for advanced NSCLC, has reached a plateau of effectiveness and achieves mostly partial responses in only 30%-40% of patients and a modest survival increase. Thus, the search for new molecularly targeted therapies is mandatory. The phosphatidylinositol 3-kinase (PI3K) pathway is frequently over activated in human cancers playing a critical role both in the initiation and progression of NSCLC. Activating mutations of this pathway play a role in the development of resistance to chemotherapy and to the Epidermal Growth Factor Receptor Tyrosine Kinase inhibitors (EGFR-TKIs) erlotinib and gefitinib. These mutations are observed in 2-5% of non-squamous NSCLC and 8-10% of squamous NSCLC. In this paper, we describe the available data and the possible future role of PI3k inhibitors in the treatment of advanced NSCLC.


PubMed | Sg Moscati Hospital Of Avellino, USLL5 and Sgmoscati Hospital Of Avellino
Type: | Journal: Frontiers in bioscience (Landmark edition) | Year: 2014

In terms of both incidence and mortality, lung tumor is the most common cancer in the world today. Among lung tumors, 80% are classified as non-small-cell lung cancer (NSCLC) and are mostly diagnosed at an advanced stage (either locally advanced or metastatic disease). Platinum-based doublet chemotherapy, the standard treatment for advanced NSCLC, has reached a plateau of effectiveness and achieves mostly partial responses in only 30%-40% of patients and a modest survival increase. Thus, the search for new molecularly targeted therapies is mandatory. The phosphatidylinositol 3-kinase (PI3K) pathway is frequently over activated in human cancers playing a critical role both in the initiation and progression of NSCLC. Activating mutations of this pathway play a role in the development of resistance to chemotherapy and to the Epidermal Growth Factor Receptor Tyrosine Kinase inhibitors (EGFR-TKIs) erlotinib and gefitinib. These mutations are observed in 2-5 % of non-squamous NSCLC and 8-10 % of squamous NSCLC. In this paper, we describe the available data and the possible future role of PI3k inhibitors in the treatment of advanced NSCLC.

Loading Sgmoscati Hospital Of Avellino collaborators
Loading Sgmoscati Hospital Of Avellino collaborators